BBIO vs NVS
BridgeBio Pharma, Inc. vs Novartis AG — AI-powered side-by-side comparison
BBIO
BridgeBio Pharma, Inc.
65
Insufficient Data
VS
| Metric | BBIO | NVS |
|---|
| AI Score |
65
|
75
|
| Price |
$83.71
|
$154.64
|
| P/E Ratio |
-23.38×
|
23.55×
|
| ROE |
35.1%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
93.1%
|
74.3%
|
| Debt / Equity |
-0.99×
|
1.18×
|
| Dividend Yield |
0.0%
|
2.9%
|
| RSI (14) |
56.9
|
57.7
|
| Beta |
0.983
|
0.462
|
| Expected Upside |
—
|
+2.4%
|
AI Committee View
Current Innellis committee reasoning for BBIO versus NVS.
NVS leads by 10 points.
NVS scores 75/100 (Buy) versus BBIO at 65/100 (Insufficient Data).
BBIO Committee View
67% agreement
3 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical